Book Summary
Bad Blood: Secrets and Lies in a Silicon Valley Startup is John Carreyrou’s devastating account of Theranos, the blood-testing startup that reached a $9 billion valuation on technology that didn’t work. Founder Elizabeth Holmes — a Stanford dropout in a black turtleneck, hailed as the next Steve Jobs — raised hundreds of millions from investors including Rupert Murdoch and Betsy DeVos, assembled a board of political heavyweights, and partnered with Walgreens, all while her company’s machines failed basic accuracy tests and the lab secretly ran samples on commercial analyzers. Carreyrou, the Wall Street Journal reporter whose investigation brought the company down, tells the story through the whistleblowers who risked their careers to talk to him. It’s a thriller, a tragedy, and the most important cautionary tale in modern investing.
Who is John Carreyrou?
John Carreyrou is a Pulitzer Prize-winning investigative reporter who spent years covering Theranos for The Wall Street Journal, breaking the story in 2015 that the company’s technology was a fraud. His reporting — built on dozens of brave former employees who spoke despite threats and surveillance — ultimately led to the company’s collapse, criminal charges, and Holmes’s conviction on fraud charges in 2022. Bad Blood (2018) expanded his reporting into a full narrative and won the Financial Times Business Book of the Year award. Carreyrou later founded a newsletter covering corporate fraud. He is the rare journalist whose work didn’t just describe history but changed its course.
Lessons From Bad Blood
Charisma is not diligence. Holmes raised billions on the strength of story, secrecy, and star power — a board featuring Henry Kissinger, George Shultz, and James Mattis — while doing almost no technical due diligence. Not one major investor hired an independent expert to verify the core claim: that Theranos could run hundreds of tests on a finger-prick of blood. For investors, the lesson is blunt and permanent: verify the technology, not the narrative. If you can’t evaluate it yourself, find someone who can.
Secrecy is a red flag. Theranos justified its extreme secrecy as protecting trade secrets. In reality, secrecy was the mechanism of the fraud — it prevented investors, partners, regulators, and even most employees from seeing that the Edison machines didn’t work. Legitimate breakthrough companies publish, peer-review, and demo. When a company raising billions won’t let experts kick the tires, that’s not stealth mode — that’s a warning.
Cultures of fear hide the truth. Inside Theranos, questioning the technology meant being fired, surveilled, or sued. Holmes and her lieutenant Sunny Balwani ran the company through intimidation, and the few employees who understood the fraud were isolated. As an investor or board member, the internal culture of a company is itself diligence material: organizations that punish dissent are organizations with something to hide.
Prestige is not verification. The Theranos board was a hall of fame of American power — and almost none of them understood blood diagnostics. Their names lent credibility that the science never earned. Walgreens partnered without proper validation. The lesson: big names on the letterhead are marketing, not due diligence. Every investor in the deal outsourced their judgment to someone else’s reputation, and the chain of borrowed credibility held until Carreyrou pulled the thread.
Whistleblowers are the immune system. The heroes of Bad Blood are young employees — Tyler Shultz, Erika Cheung, and others — who risked careers and legal threats to tell the truth. Every fraud needs silence to survive; every exposure starts with one person refusing to be silent. For investors, it means: when insiders are talking, listen. The market eventually prices in the truth, but the early listeners keep their money.
FOMO is the enemy. Investors piled into Theranos partly because everyone else was piling in — the social proof of famous co-investors substituted for analysis. The fear of missing the next Apple overrode every skeptical instinct. It’s the same dynamic behind every bubble, and Bad Blood is its purest case study: when the pitch is “get in before it’s too late,” that’s exactly when to slow down.
Criticisms of the Book
Bad Blood is so gripping that its very readability is the main criticism: it can make fraud detection feel like a spectator sport rather than a discipline. The book is light on systematic frameworks — it’s a story, not a manual, and readers looking for a checklist for spotting the next Theranos will need to extract the principles themselves. Some have also noted that the book’s focus on Holmes as a singular villain slightly understates the ecosystem’s complicity: the investors, board members, journalists, and partners who enabled the fraud largely escaped with reputations intact. And a few of the lab-technical passages are dense for non-scientific readers. None of this diminishes the achievement — it’s the best-reported business book of the last decade — but it’s worth reading as a case study to learn from, not just a thriller to enjoy.
Who is This Book For?
This book is for every investor, full stop — public or private, professional or amateur. If you allocate capital to anything you don’t fully understand, Bad Blood is mandatory: it’s the most vivid demonstration ever written of what happens when narrative replaces verification. It’s also for anyone fascinated by Silicon Valley, startup culture, or true-crime narratives — the reporting is so good it transcends the genre. Founders should read it as a mirror: the line between visionary storytelling and fraud is thinner than the industry admits, and Holmes crossed it one small exaggeration at a time. There’s no reader who won’t come away sharper.
Final Thoughts
Bad Blood is the rare book that is both unputdownable and genuinely useful. Carreyrou didn’t just document a fraud; he gave investors a permanent reference point — the next time a charismatic founder with a secretive breakthrough and a star-studded board comes calling, you’ll hear the echo of Theranos. The book’s deepest lesson isn’t about Holmes at all: it’s about the rest of us, and how easily intelligence, prestige, and FOMO combine to suspend disbelief. In a market that runs on stories, the ability to distinguish a story from a fact is the most valuable skill an investor can have. This book teaches it better than any other.
